secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030832
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics cuts 50% of workforce, discontinues two CAR T programs
----------------------------------------------------------------------------

- Reducing workforce by ~50%; expected to substantially complete by June 2025.
- Discontinuing all development for ATA3219 and ATA3431, including CAR T clinical studies.
- Estimated severance and related benefits of $3.0 million, primarily one-time cash charges.
- Additional details to be provided in the Q1 2025 10-Q filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025030832/0000950170-25-030832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025030832/atra-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer